[Dupilumab (atopic dermatitis, 6 months to 5 years) – Benefit assessment according to §35a Social Code Book V]

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018005092
Original Title: Dupilumab (atopische Dermatitis, 6 Monate bis 5 Jahre)
Project Status: Completed
Year Published: 2023
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
MeSH Terms
  • Dermatitis
  • Dermatitis, Atopic
  • Child
  • Child, Preschool
  • Antibodies, Monoclonal, Humanized
  • Dupilumab
  • Dermatitis – Atopic
  • Child – Preschool
  • Infant
  • Benefit Assessment
  • NCT02260986
  • NCT03346434
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: <p>Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.